DNA topoisomerases participate in fragility of the oncogene RET

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Dillon, Laura W ^a   Pierce, Levi C T ^b   Lehman, Christine E ^a   Nikiforov, Yuri E ^c   Wang, Yuh Hwa ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APHIDICOLIN; BETULIC ACID; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); MERBARONE; DNA TOPOISOMERASE INHIBITOR; PROTEIN RET; TOP1 PROTEIN, HUMAN;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DNA REPLICATION; DNA SECONDARY STRUCTURE; DNA STRAND BREAKAGE; DNA STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; FRAGILE SITE BREAKAGE; GENE LOCATION; GENE MAPPING; GENETIC DAMAGE; HUMAN; HUMAN CELL; INTRON; LIGATION MEDIATED POLYMERASE CHAIN REACTION; MOLECULAR RECOGNITION; NUCLEIC ACID ANALYSIS; ONCOGENE RET; THYROID CELL; BIOSYNTHESIS; CELL LINE; CHEMISTRY; CONFORMATION; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ONCOGENE; PROTEIN DEGRADATION;

APHIDICOLIN; BASE SEQUENCE; CELL LINE; DNA; DNA BREAKS; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; HUMANS; INTRONS; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; ONCOGENES; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-RET; TOPOISOMERASE INHIBITORS;

EID: 84894568328     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075741     Document Type: Article

References (81)

1. Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292-306. doi:10.1038/nrc1836. PubMed: 16557281.
2. Nikiforov YE, Nikiforova MN (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7: 569-580. doi:10.1038/nrendo. 2011.142. PubMed: 21878896.
3. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M et al. (2012) KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18: 375-377. doi: 10.1038/nm.2644. PubMed: 22327624.
4. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S et al. (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18: 378-381. doi: 10.1038/nm.2658. PubMed: 22327623.
5. Nikiforov YE (2002) RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13: 3-16. doi:10.1385/EP:13:1:03. PubMed: 12114746.
6. Chen AY, Jemal A, Ward EM (2009) Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115: 3801-3807. doi:10.1002/cncr.24416. PubMed: 19598221.
7. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A et al. (2009) Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 18: 784-791. doi:10.1158/1055-9965.EPI-08-0960. PubMed: 19240234.
8. Nikiforova MN, Nikiforov YE (2008) Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8: 83-95. doi:10.1586/14737159.8.1.83. PubMed: 18088233.
9. Gandhi M, Dillon LW, Pramanik S, Nikiforov YE, Wang YH (2010) DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene 29: 2272-2280. doi:10.1038/onc. 2009.502. PubMed: 20101222.
10. Durkin SG, Glover TW (2007) Chromosome fragile sites. Annu Rev Genet 41: 169-192. doi:10.1146/annurev.genet.41.042007.165900. PubMed: 17608616.
11. Dillon LW, Burrow AA, Wang YH (2010) DNA instability at chromosomal fragile sites in cancer. Curr Genomics 11: 326-337. doi: 10.2174/138920210791616699. PubMed: 21286310.
12. Burrow AA, Williams LE, Pierce LC, Wang YH (2009) Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC Genomics 10: 59. doi:10.1186/1471-2164-10-59. PubMed: 19183484.
13. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S et al. (2010) Signatures of mutation and selection in the cancer genome. Nature 463: 893-898. doi:10.1038/nature08768. PubMed: 20164919.
14. Durkin SG, Ragland RL, Arlt MF, Mulle JG, Warren ST et al. (2008) Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc Natl Acad Sci U S A 105: 246-251. doi:10.1073/pnas. 0708097105. PubMed: 18162546.
15. McAvoy S, Ganapathiraju SC, Ducharme-Smith AL, Pritchett JR, Kosari F et al. (2007) Non-random inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res 118: 260-269. doi: 10.1159/000108309. PubMed: 18000379.
16. Sutherland GR (2003) Rare fragile sites. Cytogenet Genome Res 100: 77-84. doi:10.1159/000072840. PubMed: 14526166.
17. Glover TW (2006) Common fragile sites. Cancer Lett 232: 4-12. doi: 10.1016/j.canlet.2005.08.032. PubMed: 16229941.
18. Cheng CH, Kuchta RD (1993) DNA polymerase epsilon: aphidicolin inhibition and the relationship between polymerase and exonuclease activity. Biochemistry 32: 8568-8574. doi:10.1021/bi00084a025. PubMed: 8395209.
19. Glover TW, Berger C, Coyle J, Echo B (1984) DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 67: 136-142. doi:10.1007/BF00272988. PubMed: 6430783.
20. Handt O, Baker E, Dayan S, Gartler SM, Woollatt E et al. (2000) Analysis of replication timing at the FRA10B and FRA16B fragile site loci. Chromosome Res 8: 677-688. doi:10.1023/A:1026737203447. PubMed: 11196131.
21. Hellman A, Rahat A, Scherer SW, Darvasi A, Tsui LC et al. (2000) Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol Cell Biol 20: 4420-4427. doi:10.1128/MCB.20.12.4420-4427.2000. PubMed: 10825205.
22. Le Beau, Rassool FV, Neilly ME, Espinosa R 3rd, Glover TW et al. (1998) Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum Mol Genet 7: 755-761. doi: 10.1093/hmg/7.4.755. PubMed: 9499431.
23. Pelliccia F, Bosco N, Curatolo A, Rocchi A (2008) Replication timing of two human common fragile sites: FRA1H and FRA2G. Cytogenet Genome Res 121: 196-200. doi:10.1159/000138885. PubMed: 18758159.
24. Mishmar D, Rahat A, Scherer SW, Nyakatura G, Hinzmann B et al. (1998) Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc Natl Acad Sci U S A 95: 8141-8146. doi:10.1073/pnas. 95.14.8141. PubMed: 9653154.
25. Zlotorynski E, Rahat A, Skaug J, Ben-Porat N, Ozeri E et al. (2003) Molecular basis for expression of common and rare fragile sites. Mol Cell Biol 23: 7143-7151. doi:10.1128/MCB.23.20.7143-7151.2003. PubMed: 14517285.
26. Zhang H, Freudenreich CH (2007) An AT-rich sequence in human common fragile site FRA16D causes fork stalling and chromosome breakage in S. cervisiae. Mol Cell 27: 367-379. doi:10.1016/j.molcel. 2007.06.012. PubMed: 17679088.
27. Shah SN, Opresko PL, Meng X, Lee MY, Eckert KA (2010) DNA structure and the Werner protein modulate human DNA polymerase delta-dependent replication dynamics within the common fragile site FRA16D. Nucleic Acids Res 38: 1149-1162. doi:10.1093/nar/gkp1131. PubMed: 19969545.
28. Dillon LW, Pierce LC, Ng MC, Wang YH (2013) Role of DNA secondary structures in fragile site breakage along human chromosome 10. Hum Mol Genet, Jan 12/[Epub ahead of print] PubMed: 23297364.
29. Helmrich A, Ballarino M, Tora L (2011) Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol Cell 44: 966-977. doi:10.1016/j.molcel. 2011.10.013. PubMed: 22195969.
30. Grabczyk E, Mancuso M, Sammarco MC (2007) A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res 35: 5351-5359. doi:10.1093/nar/gkm589. PubMed: 17693431.
31. Lin Y, Dent SY, Wilson JH, Wells RD, Napierala M (2010) R loops stimulate genetic instability of CTG.CAG repeats. Proc Natl Acad Sci U S A 107: 692-697. doi:10.1073/pnas.0909740107. PubMed: 20080737.
32. Reddy K, Tam M, Bowater RP, Barber M, Tomlinson M et al. (2011) Determinants of R-loop formation at convergent bidirectionally transcribed trinucleotide repeats. Nucleic Acids Res 39: 1749-1762. doi:10.1093/nar/gkq935. PubMed: 21051337.
33. Vos SM, Tretter EM, Schmidt BH, Berger JM (2011) All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol 12: 827-841. doi:10.1038/nrm3228. PubMed: 22108601.
34. Been MD, Champoux JJ (1984) Breakage of single-stranded DNA by eukaryotic type 1 topoisomerase occurs only at regions with the potential for base-pairing. J Mol Biol 180: 515-531. doi: 10.1016/0022-2836(84)90025-1. PubMed: 6098684.
35. Froelich-Ammon SJ, Gale KC, Osheroff N (1994) Site-specific cleavage of a DNA hairpin by topoisomerase II. DNA secondary structure as a determinant of enzyme recognition/cleavage. J Biol Chem 269: 7719-7725. PubMed: 8125998.
36. Jonstrup AT, Thomsen T, Wang Y, Knudsen BR, Koch J et al. (2008) Hairpin structures formed by alpha satellite DNA of human centromeres are cleaved by human topoisomerase IIalpha. Nucleic Acids Res 36: 6165-6174. doi:10.1093/nar/gkn640. PubMed: 18824478.
37. Arlt MF, Glover TW (2010) Inhibition of topoisomerase I prevents chromosome breakage at common fragile sites. DNA Repair (Amst) 9: 678-689. doi:10.1016/j.dnarep.2010.03.005. PubMed: 20413351.
38. Tuduri S, Crabbé L, Conti C, Tourrière H, Holtgreve-Grez H et al. (2009) Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol 11: 1315-1324. doi:10.1038/ncb1984. PubMed: 19838172.
39. Smanik PA, Furminger TL, Mazzaferri EL, Jhiang SM (1995) Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma. Hum Mol Genet 4: 2313-2318. doi:10.1093/hmg/4.12.2313. PubMed: 8634704.
40. Caudill CM, Zhu Z, Ciampi R, Stringer JR, Nikiforov YE (2005) Dosedependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab 90: 2364-2369. doi:10.1210/jc.2004-1811. PubMed: 15671095.
41. Mulvihill DJ, Wang YH (2004) Two breakpoint clusters at fragile site FRA3B form phased nucleosomes. Genome Res 14: 1350-1357. doi: 10.1101/gr.2304404. PubMed: 15231750.
42. Corbin S, Neilly ME, Espinosa R 3rd, Davis EM, McKeithan TW et al. (2002) Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors. Cancer Res 62: 3477-3484. PubMed: 12067991.
43. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning : a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
44. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415. doi: 10.1093/nar/gkg595. PubMed: 12824337.
45. Anderson S, DePamphilis ML (1979) Metabolism of Okazaki fragments during simian virus 40 DNA replication. J Biol Chem 254: 11495-11504. PubMed: 227871.
46. Hay RT, DePamphilis ML (1982) Initiation of SV40 DNA replication in vivo: location and structure of 5' ends of DNA synthesized in the ori region. Cell 28: 767-779. doi:10.1016/0092-8674(82)90056-3. PubMed: 6178514.
47. Bongarzone I, Butti MG, Fugazzola L, Pacini F, Pinchera A et al. (1997) Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiationassociated papillary thyroid carcinomas. Genomics 42: 252-259. doi: 10.1006/geno.1997.4685. PubMed: 9192845.
48. Jhiang SM, Caruso DR, Gilmore E, Ishizaka Y, Tahira T et al. (1992) Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene 7: 1331-1337. PubMed: 1620547.
49. Klugbauer S, Pfeiffer P, Gassenhuber H, Beimfohr C, Rabes HM (2001) RET rearrangements in radiation-induced papillary thyroid carcinomas: high prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes. Genomics 73: 149-160. doi:10.1006/geno.2000.6434. PubMed: 11318605.
50. Nikiforov YE, Koshoffer A, Nikiforova M, Stringer J, Fagin JA (1999) Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene 18: 6330-6334. doi: 10.1038/sj.onc.1203019. PubMed: 10597232.
51. Been MD, Burgess RR, Champoux JJ (1984) Nucleotide sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV40 DNA. Nucleic Acids Res 12: 3097-3114. doi:10.1093/nar/12.7.3097. PubMed: 6326051.
52. Capranico G, Binaschi M (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim Biophys Acta 1400: 185-194. doi:10.1016/S0167-4781(98)00135-3. PubMed: 9748568.
53. Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8: 641-661. PubMed: 11895891.
54. Hande KR (2008) Topoisomerase II inhibitors. Update Cancer Therapeutics 3: 13-26. doi:10.1016/j.uct.2008.02.001. PubMed: 16110609153387421270320311686011.
55. Long BH, Musial ST, Brattain MG (1985) Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 45: 3106-3112. PubMed: 3839166.
56. Pondarré C, Strumberg D, Fujimori A, Torres-León R, Pommier Y (1997) In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. Nucleic Acids Res 25: 4111-4116. doi:10.1093/nar/25.20.4111. PubMed: 9321666.
57. Ganguly A, Das B, Roy A, Sen N, Dasgupta SB et al. (2007) Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death. Cancer Res 67: 11848-11858. doi: 10.1158/0008-5472.CAN-07-1615. PubMed: 18089815.
58. Bar FM, Khanfar MA, Elnagar AY, Liu H, Zaghloul AM et al. (2009) Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors. J Nat Prod 72: 1643-1650. doi: 10.1021/np900312u. PubMed: 19691293.
59. Syrovets T, Büchele B, Gedig E, Slupsky JR, Simmet T (2000) Acetylboswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. Mol Pharmacol 58: 71-81. PubMed: 10860928.
60. Wada S, Tanaka R (2005) Betulinic acid and its derivatives, potent DNA topoisomerase II inhibitors, from the bark of Bischofia javanica. Chem Biodivers 2: 689-694. doi:10.1002/cbdv.200590045. PubMed: 17192012.
61. Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP et al. (1989) In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49: 2578-2583. PubMed: 2540903.
62. Fortune JM, Osheroff N (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage. J Biol Chem 273: 17643-17650. doi:10.1074/jbc.273.28.17643. PubMed: 9651360.
63. Abdurashidova G, Radulescu S, Sandoval O, Zahariev S, Danailov MB et al. (2007) Functional interactions of DNA topoisomerases with a human replication origin. EMBO J 26: 998-1009. doi:10.1038/sj.emboj. 7601578. PubMed: 17290216.
64. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3: 430-440. doi:10.1038/nrm831. PubMed: 12042765.
65. Postow L, Crisona NJ, Peter BJ, Hardy CD, Cozzarelli NR (2001) Topological challenges to DNA replication: conformations at the fork. Proc Natl Acad Sci U S A 98: 8219-8226. doi:10.1073/pnas. 111006998. PubMed: 11459956.
66. Liu LF, Wang JC (1987) Supercoiling of the DNA template during transcription. Proc Natl Acad Sci U S A 84: 7024-7027. doi:10.1073/pnas.84.20.7024. PubMed: 2823250.
67. Wu HY, Shyy SH, Wang JC, Liu LF (1988) Transcription generates positively and negatively supercoiled domains in the template. Cell 53: 433-440. doi:10.1016/0092-8674(88)90163-8. PubMed: 2835168.
68. Drolet M, Bi X, Liu LF (1994) Hypernegative supercoiling of the DNA template during transcription elongation in vitro. J Biol Chem 269: 2068-2074. PubMed: 8294458.
69. Li X, Manley JL (2005) Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell 122: 365-378. doi:10.1016/j.cell.2005.06.008. PubMed: 16096057.
70. Lin Y, Wilson JH (2011) Transcription-induced DNA toxicity at trinucleotide repeats: double bubble is trouble. Cell Cycle 10: 611-618. doi:10.4161/cc.10.4.14729. PubMed: 21293182.
71. Lemoine NR, Mayall ES, Jones T, Sheer D, McDermid S et al. (1989) Characterisation of human thyroid epithelial cells immortalised in vitro by simian virus 40 DNA transfection. Br J Cancer 60: 897-903. doi: 10.1038/bjc.1989.387. PubMed: 2557880.
72. Allan JM, Travis LB (2005) Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 5: 943-955. doi:10.1038/nrc1749. PubMed: 16294218.
73. Boffetta P, Kaldor JM (1994) Secondary malignancies following cancer chemotherapy. Acta Oncol 33: 591-598. doi: 10.3109/02841869409121767. PubMed: 7946433.
74. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Vaughan Hudson B, MacLennan KA (1993) Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br J Cancer 68: 1006-1011. doi:10.1038/bjc. 1993.470. PubMed: 8217588.
75. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E et al. (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89: 1429-1439. doi:10.1093/jnci/89.19.1429. PubMed: 9326912.
76. Kim MS, Sim YS, Lee SY, Jeon DG (2008) Secondary thyroid papillary carcinoma in osteosarcoma patients: report of two cases. J Korean Med Sci 23: 149-152. doi:10.3346/jkms.2008.23.1.149. PubMed: 18303218.
77. Venkitaraman R, Affolter A, Ahmed M, Thomas V, Pritchard-Jones K et al. (2008) Childhood papillary thyroid cancer as second malignancy after successful treatment of rhabdomyosarcoma. Acta Oncol 47: 469-472. doi:10.1080/02841860701864676. PubMed: 18348005.
78. de Vathaire F, Hawkins M, Campbell S, Oberlin O, Raquin MA et al. (1999) Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br J Cancer 79: 1884-1893. doi:10.1038/sj.bjc.6690300. PubMed: 10206309.
79. Gow KW, Lensing S, Hill DA, Krasin MJ, McCarville MB et al. (2003) Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature. J Pediatr Surg 38: 1574-1580. doi:10.1016/S0022-3468(03)00563-3. PubMed: 14614703.
80. Smith MB, Xue H, Strong L, Takahashi H, Jaffe N et al. (1993) Fortyyear experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy. J Pediatr Surg 28: 1342-1348; discussion 1348-1349 doi: 10.1016/S0022-3468(05)80325-2. PubMed: 8263699.
81. Vane D, King DR, Boles ET Jr. (1984) Secondary thyroid neoplasms in pediatric cancer patients: increased risk with improved survival. J Pediatr Surg 19: 855-860. doi:10.1016/S0022-3468(84)80384-X. PubMed: 6097662.